Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of BIVV020 (SAR445088) for prevention and treatment of antibody-mediated rejection in adult kidney transplant recipients
2021-000010-41Phase 2Active
- Sponsor
- Sanofi
- Start
- Aug 2021
- Modality
- IgG Antibodies → Naked Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in Antibody-mediated kidney allograft rejection (AMR) and graft rejection comparing BIVV020 plus standard-of-care with Standard-of-care only (2 arms). Primary endpoint: Treatment failure rate (Cohort A, primary). Started Aug 2021; status: active.
02
Drugs
riliprubart
03
Conditions
Antibody-mediated kidney allograft rejection (AMR)graft rejection
Beyond the preview
Go deeper on 2021-000010-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000010-41.